Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hexas Biomaterials is a regenerative materials company that utilizes plant biotechnology to produce sustainable, carbon-neutral raw materials. The company's flagship product, Xylomer, is a proprietary perennial grass variety engineered to provide a high-yield, non-genetically modified alternative to wood and fossil fuel-based feedstocks. Hexas focuses on delivering these biomaterials for use in biofuels, biochemicals, and structural products, aiming to reduce reliance on traditional timber and petroleum. By providing a scalable and stable supply chain for bio-based industries, the company supports the global transition toward a circular economy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hexas.